Expertise in
11
conditions

Dr. Anita J. Kumar

Internal Medicine
Foundation Medical Partners Inc
280 Main St, 
Nashua, NH 
Expertise in
11
conditions
Foundation Medical Partners Inc
280 Main St, 
Nashua, NH 

Overview

Anita Kumar is a primary care provider, practicing in Internal Medicine in Nashua, New Hampshire.

Dr. Kumar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma.

She is actively involved in clinical research, co-authoring 127 peer reviewed articles and participating in 6 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Foundation Medical Partners Inc
280 Main St, Nashua, NH 03060
Other Locations
Henry C. Nevins Home for the Aged Alzheimer
12 Ingalls Ct, Methuen, MA 01844

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine
Study Phase: Not Applicable
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2025
Intervention Type: Other, Device
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, High-Dose Cytarabine (HIDAC)
Study Phase: Phase 2
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological
Study Drugs: Mogamulizumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

127 Total Publications

Modern Management of Mantle Cell Lymphoma.
Modern Management of Mantle Cell Lymphoma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Expertise in
24
conditions
Dr. Adnan J. Majid
Internal Medicine
Before you request

Medical And Surgical Specialties

200 Boylston Street, 
Chestnut Hill, MA 
 (33.4 miles away)
617-632-8252
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adnan Majid is a primary care provider, practicing in Internal Medicine in Chestnut Hill, Massachusetts. Dr. Majid is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Tracheobronchomalacia, Acquired Tracheomalacia, Parapneumonic Pleural Effusion, Advanced Bronchoscopy, and Endoscopy. Dr. Majid is board certified in American Board Of Internal Medicine. Dr. Majid is currently accepting new patients.

Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Expertise in
24
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Before you request

BIDMC - Division Of Gastroenterology/Liver Center

110 Francis Street, 
Boston, MA 
 (34.0 miles away)
617-632-1070
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Nezam Afdhal is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. Dr. Afdhal is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Afdhal is currently accepting new patients.

Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine
Expertise in
22
conditions
Dr. Gabriela S. Hobbs
Internal Medicine

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (33.7 miles away)
617-724-1124
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gabriela Hobbs is a primary care provider, practicing in Internal Medicine in Boston, Massachusetts. She has been practicing medicine for over 18 years. Dr. Hobbs is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Bone Marrow Aspiration, and Colonoscopy. Dr. Hobbs is currently accepting new patients.

Frequently Asked Questions about Dr. Anita J. Kumar

How do I make an appointment with Dr. Anita J. Kumar?

You can book an appointment with Dr. Anita J. Kumar by calling their office at 603-577-2759. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anita J. Kumar a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anita J. Kumar is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anita J. Kumar specialize in?

While Dr. Anita J. Kumar is a Internal Medicine, they have specific expertise in Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Anita J. Kumar participate in research or clinical trials?

Yes. Dr. Anita J. Kumar has published 127 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Anita J. Kumar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anita J. Kumar accept my insurance?

Dr. Anita J. Kumar accepts most major insurance plans, including Cigna and Horizon Healthcare. We recommend calling the office directly at 603-577-2759 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
View All 64 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile